Opinion: STAT+: The U.S.-China biotech crackdown may hurt the scientists America needs the most

The article discusses concerns that the U.S.-China biotech crackdown could harm American scientists, as China's biotech sector grows, contributing 34% of global new drugs in clinical development and out-licensing deals reaching $137.7 billion by 2025. It highlights tensions over intellectual property fears and state-run companies in China.